These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33046866)

  • 1. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia.
    Xie G; Ivica NA; Jia B; Li Y; Dong H; Liang Y; Brown D; Romee R; Chen J
    Nat Biomed Eng; 2021 May; 5(5):399-413. PubMed ID: 33046866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.
    Dong H; Ham JD; Hu G; Xie G; Vergara J; Liang Y; Ali A; Tarannum M; Donner H; Baginska J; Abdulhamid Y; Dinh K; Soiffer RJ; Ritz J; Glimcher LH; Chen J; Romee R
    Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2122379119. PubMed ID: 35696582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo.
    He H; Vedia RA; Lu S; Li Q; Cox KR; St John L; Sergeeva A; Clise-Dwyer K; Alatrash G; Shpall EJ; Ma Q; Molldrem JJ
    Cytotherapy; 2024 Nov; 26(11):1331-1340. PubMed ID: 39033444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
    van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
    J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
    Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
    Front Immunol; 2021; 12():686439. PubMed ID: 34616392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
    Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
    Front Immunol; 2018; 9():3153. PubMed ID: 30713535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
    Maruta M; Ochi T; Tanimoto K; Asai H; Saitou T; Fujiwara H; Imamura T; Takenaka K; Yasukawa M
    Sci Rep; 2019 Sep; 9(1):13293. PubMed ID: 31527633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
    Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
    J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.
    Bézie S; Charreau B; Vimond N; Lasselin J; Gérard N; Nerrière-Daguin V; Bellier-Waast F; Duteille F; Anegon I; Guillonneau C
    Blood Adv; 2019 Nov; 3(22):3522-3538. PubMed ID: 31730699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
    Wang XY; Bian MR; Lin GQ; Yu L; Zhang YM; Wu DP
    Eur J Haematol; 2024 Jan; 112(1):83-93. PubMed ID: 37712633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
    Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
    J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.
    Sergeeva A; Alatrash G; He H; Ruisaard K; Lu S; Wygant J; McIntyre BW; Ma Q; Li D; St John L; Clise-Dwyer K; Molldrem JJ
    Blood; 2011 Apr; 117(16):4262-72. PubMed ID: 21296998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.
    Greiner J; Ono Y; Hofmann S; Schmitt A; Mehring E; Götz M; Guillaume P; Döhner K; Mytilineos J; Döhner H; Schmitt M
    Blood; 2012 Aug; 120(6):1282-9. PubMed ID: 22592607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
    Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
    Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
    Sauer T; Parikh K; Sharma S; Omer B; Sedloev D; Chen Q; Angenendt L; Schliemann C; Schmitt M; Müller-Tidow C; Gottschalk S; Rooney CM
    Blood; 2021 Jul; 138(4):318-330. PubMed ID: 34323938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.